Medicare Advantage Pays Less Per Visit and Demands More Paperwork: How to Rebuild Your Home Health Payer Mix Strategy in 2026
Medicare Advantage is changing the economics of home health, often combining lower revenue per visit with more administrative work. This article shows how that shift can affect margins and buyer underwriting, and why payer-level reporting matters before a sale or succession plan. Owners will find a practical list of monthly measures to track, plus a hypothetical example of how differences in data quality can change buyer-accepted EBITDA and enterprise value. Senate Healthcare LLC is evaluating home health or hospice acquisitions and welcomes confidential conversations with owners considering their next step.
11/19/20266 min read


This article explains how the shift toward Medicare Advantage (MA) can affect a home health agency’s margins, exit readiness, and valuation. It offers practical steps to rebuild your agency payer mix strategy around payer-level performance, buyer diligence, and sustainable growth.
Quick-Scan Summary
Who this is for
Home health owners with $2 million to $10 million in revenue who are considering a sale, partnership, or succession plan.
Operators whose Medicare Advantage census has grown without a deliberate contracting and reporting strategy.
Owners of home health or hospice agencies who want to understand how payer risk can affect buyer underwriting.
Key takeaways
Homecare Homebase data reported by Home Health Care News shows average revenue per visit of $266 for traditional Medicare and $206 for MA, alongside approximately 13% more weekly office workflow for MA patients.
A growing MA share can affect valuation twice: through payer-level margins and through buyer confidence in the durability of reported EBITDA.
Buyers need payer-level reporting to assess reimbursement, collections, denials, and administrative workload.
A high MA share does not automatically mean a low valuation. Clear data and evidence of managed exposure can help a buyer underwrite the business with greater confidence.


The payer mix many agencies built for has changed
Many owners designed their staffing, workflows, and contracts when traditional Medicare represented roughly two thirds of the business. But in Homecare Homebase’s dataset, MA accounted for 49.5% of patients, up 31% since 2016.
At the National Alliance for Care at Home Annual Meeting & Expo, Homecare Homebase reported average revenue per visit of $266 for traditional Medicare compared with $206 for MA. That is a $60 difference, or about 23% less revenue per visit. Weekly office workflow for MA patients was about 13% higher, while weekly visits per patient and rehospitalization rates were roughly the same across the two populations, according to the company’s data as reported by Home Health Care News.
That gap deserves attention, but it is not a universal rate comparison for every agency or plan. Contract terms, patient needs, markets, and operations differ. The actionable question is whether your own MA reimbursement covers the clinical work and the added time required for authorizations, follow-up, denials, and appeals.
The Commonwealth Fund’s 2026 issue brief adds important context: MA enrollees average 1.8 fewer visits per episode than traditional Medicare beneficiaries. Interviewed agencies said some MA payments were roughly half the cost of providing care. Referral rejection rates were three to four times higher for certain MA plans, not necessarily across all plans. The brief also describes narrow and “ghost” networks and notes that traditional Medicare revenue may cross-subsidize MA underpayments, obscuring their effect.
Margin pressure can become valuation pressure
The pressure is not limited to individual contracts. Home Health Care News reported SimiTree data showing traditional Medicare margins have remained relatively steady since PDGM, while the cost-report category that includes MA has consistently operated at a loss. That category also includes other payers, so it does not isolate MA’s results. The same article noted overall home health margins were around 7% when PDGM launched and hovered around 3% over the last three years, based on CMS data through 2024. Total RN visit costs approached $230, about $60 higher than at PDGM’s inception.
Payment policy adds another layer. MedPAC’s October 2026 payment basics lists a 2026 base payment of $2,038.22 for a 30-day period. The 2026 update was 2.4%, offset by a 4.0% adjustment required by the Bipartisan Budget Act of 2018. MedPAC also reports that 2.7 million beneficiaries used home health care in 2024, with total payments of $16.0 billion.
For owners, the connection is direct: buyer diligence looks beyond reported EBITDA to the quality and durability of earnings. Auxo Capital Advisors’ 2026 valuation guide describes directional ranges of roughly 4.0x to 8.5x normalized EBITDA for founder-led lower-middle-market home health and hospice assets. Its guide emphasizes that multiples apply to buyer-accepted normalized EBITDA, not simply reported EBITDA. Payer mix can affect reimbursement predictability, collections, margin quality, denial risk, and deal structure.
Arnall Golden Gregory’s 2026 M&A analysis describes tighter underwriting and less tolerance for EBITDA add-backs, with adjustments moving from roughly 20% of EBITDA to a more constrained 12% to 15% range. Buyers are placing greater weight on documentation, compliance infrastructure, revenue durability, and consistent data.
A payer-mix self-check


These are not pass-or-fail categories. A buyer’s response depends on the evidence, contract economics, and operational controls behind the mix.
What the valuation math can look like
Hypothetical illustration only. These figures are illustrative, not a market quote or forecast. Consider two agencies, each with illustrative revenue of $8.0 million and illustrative reported EBITDA of $1.0 million.
Agency A has an illustrative mix of 60% traditional Medicare visits and 25% MA visits. It tracks payer-level collections, denial trends, and authorization labor monthly. For illustration, assume a buyer accepts $1.0 million of normalized EBITDA and applies a hypothetical 6.5x multiple: $1.0 million × 6.5 = $6.5 million enterprise value.
Agency B has an illustrative MA share of 55% of visits and no payer-level reporting. For illustration, assume a buyer normalizes for rate pressure and includes the estimated cost of currently unstaffed authorization work. If that review reduces buyer-accepted EBITDA to a hypothetical $800,000, and the buyer applies a hypothetical 4.75x multiple: $800,000 × 4.75 = $3.8 million enterprise value.
Under these assumptions, the illustrative enterprise value difference is $2.7 million. The example does not predict what any buyer will offer. It shows how weaker visibility can affect both accepted EBITDA and the multiple used in underwriting.


Track what the buyer will need to understand
Build a monthly payer dashboard that includes:
Net reimbursement per completed visit by payer.
Authorized visits compared with clinically ordered visits.
Denials and appeal overturn rates.
Authorization labor hours per 100 MA episodes.
Days in accounts receivable by payer.
EBITDA margin by payer.
Revenue concentration by individual MA plan.
Referral volume by payer and referral source
Look at trends by plan and branch, not just blended totals. Where a contract’s economics are weak, use documented clinical outcomes and service data to support negotiations. Home Health Care News reports that plans have become more receptive to episodic, Medicare-like MA contracts, and that providers should bring clinical outcomes data to those discussions. For hospice operators, payer mix has a different operating context, but the same buyer questions about revenue durability, reporting quality, and concentration still matter.
Two common owner decision points
One owner may notice that MA census has grown through referral relationships, not through a deliberate contracting decision. The immediate choice is whether to renegotiate, build plan-level reporting, or continue accepting volume without knowing the full cost to serve.
Another owner may be planning succession and realize that one experienced employee carries much of the authorization knowledge. That is not a reason to assume a sale is out of reach. It is a signal to document the work, measure its cost, and build a process that does not depend on a single person.
Plain-Language Glossary
Payer mix: The share of an agency’s patients, visits, or revenue associated with each payer.
Normalized EBITDA: Earnings adjusted to reflect the buyer’s view of ongoing, supportable operating performance.
Buyer underwriting: The buyer’s analysis of earnings, risks, and assumptions before deciding on price and deal terms.
Enterprise value: The value of the operating business before adjustments such as debt and working capital.
Cross-subsidy: When stronger earnings from one payer help cover losses from another.
So what should you do now?
Build a payer-level view of reimbursement, denials, collections, and margin before making contract decisions.
Quantify authorization workload and assign clear ownership so the process is not dependent on one employee.
Review your largest MA plans and referral sources for concentration and contract risk.
Organize the data a buyer would need to assess earnings quality, even if a sale is not imminent.
Explore a sale or partnership with Senate Healthcare
Senate Healthcare LLC is the buyer and strategic partner evaluating home health or hospice acquisitions. We work with owners who are considering a sale, partnership, or succession plan, including agencies that are still improving reporting or reducing operational risk. A confidential conversation can help determine whether an acquisition or partnership with Senate Healthcare could support your goals and a more orderly transition.
Unlock Your 30-Minute Agency Succession Review
Maybe you're ready to expand your reach, or perhaps it's time to consider your legacy and the future of your business. Either way, it all begins with a conversation. Schedule a confidential, no-obligation call to explore what the future might hold for you and your business.
Complete the form, and we'll reach out for a chat...


© 2025 SENATE HEALTHCARE LLC.
ALL RIGHTS RESERVED


